Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.05 and traded as high as $0.05. Mateon Therapeutics shares last traded at $0.05, with a volume of 16,565 shares trading hands.
Mateon Therapeutics Trading Up 1.6%
The stock’s 50 day simple moving average is $0.05 and its 200 day simple moving average is $0.05.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Stories
- Five stocks we like better than Mateon Therapeutics
- How to Effectively Use the MarketBeat Ratings Screener
- Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4
- 3 Fintech Stocks With Good 2021 Prospects
- Why Datadog Is the AI Infrastructure Firm to Watch Out For
- Breakout Stocks: What They Are and How to Identify Them
- 4 Stocks Every AI ETF Is Buying—And They’re Not What You Think
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
